ARNI (Arno Therapeutics) EBIT per Share: $-0.43 (TTM As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Arno Therapeutics EBIT per Share?

Arno Therapeutics ARNI EBIT per Share is $-0.43 as of Sep. 2016.

Arno Therapeutics's EBIT per Share for the three months ended in Sep. 2016 was $-0.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.43.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Arno Therapeutics's EBIT per Share or its related term are showing as below:

ARNI's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Arno Therapeutics's EBIT for the three months ended in Sep. 2016 was $-3.85 Mil.

Arno Therapeutics  (OTCPK:ARNI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Arno Therapeutics EBIT per Share Related Terms

Arno Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Arno Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arno Therapeutics EBIT per Share Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -1.77 -2.81 0.31 -0.56

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.19 -0.10 -0.05 -0.09

Arno Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Arno Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2015 is calculated as

EBIT per Share(A: Dec. 2015 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.48/20.409
=-0.56

Arno Therapeutics's EBIT per Share for the quarter that ended in Sep. 2016 is calculated as

EBIT per Share(Q: Sep. 2016 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.849/44.706
=-0.09

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.43 mean?
Arno Therapeutics (ARNI) has a EBIT per Share of $-0.43 as of Sep. 2016. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arno Therapeutics and its competitors.
Is Arno Therapeutics' EBIT per Share too high?
Arno Therapeutics' current EBIT per Share is $-0.43.
How does Arno Therapeutics' EBIT per Share compare to PLPL and BTHE?
Arno Therapeutics' EBIT per Share of $-0.43 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arno Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arno Therapeutics's current EBIT per Share is $-0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arno Therapeutics stock overvalued right now?
Arno Therapeutics (ARNI) has a current EBIT per Share of $-0.43. The current EBIT per Share is $-0.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Arno Therapeutics (ARNI), the current EBIT per Share is $-0.43 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arno Therapeutics Business Description

Address 200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.